NanoRepro AG issues revenue guidance
Analysis based on 7 articles · First reported Sep 03, 2026 · Last updated Sep 07, 2026
The revenue guidance provides greater visibility into NanoRepro's growth trajectory, supporting a positive outlook and reinforcing the BUY rating from NuWays AG. The announcement is likely to have a modest positive impact on NanoRepro's share price, reflecting confidence in the company's medium-term growth and M&A optionality.
NanoRepro, a German multi-brand consumer health platform, published short-, medium-, and long-term revenue guidance ahead of its annual general meeting. The company guided for approximately EUR 18 million in revenue for fiscal year 2026, implying double-digit growth of about 12.5% year-over-year, slightly below analyst expectations. For fiscal year 2028, management targets around EUR 28 million in revenue, and for fiscal year 2030, approximately EUR 40 million, implying a strong compound annual growth rate of about 20% from fiscal year 2025. The guidance reflects both organic growth and potential future acquisitions, supported by a proposal to increase authorized capital by EUR 1.9 million to EUR 7.1 million, which would allow shares to be issued as acquisition consideration. NuWays AG, the covering research firm, reiterated its BUY rating with a target price of EUR 4.40, adjusting its revenue forecasts to align with the new guidance. The company also recently completed the acquisition of the remaining 67% stake in Hyped About Science GmbH, which will be renamed Alphabiol GmbH, consolidating its nutritional elixirs brand as a third pillar alongside rapid testing kits and PAEDIPROTECT.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard